The healthcare industry is heavily investing in developing safe and effective treatments using cell therapy technologies as an alternative to traditional treatments.
The result: The cell therapy bioprocessing market is ballooning at breakneck speed.
The global cell therapy bioprocessing market size is predicted to hit a revenue of a staggering $30,052.61M by 2028—up from $ 11,192.50M in 2020. The market is expected to grow at a CAGR of 13.14% during the forecast period between 2020 and 2028, according to a report by Insight Partners published in medgadget.
Cell therapy bioprocessing
Cell therapy bioprocessing is a subfield of bioprocess technology that blurs the lines between bioprocessing (biopharmaceutical manufacturing) and cell therapy.
The goal is to develop robust and reproducible manufacturing processes for producing therapeutic cells by substituting, rebuilding, repairing, or regenerating damaged cells, tissues, and organs.
Cell therapy bioprocessing holds great promise to revolutionize healthcare and treat chronic conditions—such as cancers, age-related blindness, macular degeneration, stroke, and more.
Driving Forces Behind the Cell Therapy Bioprocessing Market Growth
The growing need to efficiently treat chronic ailments has pushed research activities in cell and gene therapy bioprocessing which, in turn, is likely to propel the market’s growth over the coming years.
The increasing number of clinical trials conducted or underway is another leading factor contributing to the rapid growth of the cell therapy bioprocessing market.
Case in point: as of 2022, 1221 active clinical trials were conducted on cell and gene therapies, among which 342 were in phase 1/1b.
The report marks the advancement in genome editing as another driving force behind the cell therapy market growth.
By allowing scientists to add, remove, or alter DNA in the genome at specific points, genome editing can provide effective treatment solutions for chronic ailments.
Medical scientists hope that genome editing will act as a step-change in treating monogenic hereditary diseases—such as hemophilia, cystic fibrosis, muscular dystrophy, and Huntington’s disease.
Interventions into the immune system can also help cure acquired diseases—e.g., AIDS or cancer. The potential of genome editing technologies, such as TALENs and Zinc-finger nuclease, has opened avenues in the modern therapeutic sector having the potential to accelerate market growth.
Furthermore, the gradual invention of innovative technologies to support the development of avant-garde therapies has further aided market expansion. For example, CRISPR-Cas9 is one of the widely adopted genome editing technologies that yield higher accuracy. Being the cheapest yet highly efficient system to alter genetic traits in a cell, CRISPR-Cas9 has significantly fueled research activities.
The Cell Therapy Bioprocessing Market Segmentation
According to the report, by technology, the market is segmented into a) lyophilization, b) bioreactor, c) electro-spinning, d) ultrasonic lysis, e) control-flow centrifugation, f) viral vector technology, g) cell immortalization technology, and h) genome editing technology. The bioreactor segment reigned in the cell therapy bioprocessing market, accounting for the largest revenue share in 2020. On the other hand, the genome editing technology segment is forecast to grow at the highest CAGR of 14.5% through the projection period.
By cell type, the market is segmented into a) immune cell, b) stem cell, c) hematopoietic stem cells, d) pluripotent stem cell, and e) human embryonic stem cell. The stem cell was the highest market-share segment in 2020 and is projected to record the highest CAGR of 14.0% during the forecast period.
In addition, by indication, the market is segmented into a) oncology, b) orthopedics, c) cardiovascular disease (CVD), c) wound healing, and more. Among the segments, oncology held the largest market share in 2020 and is foreseen to record the highest CAGR of 14.3% through the projection period.
The report highlights some of the key players in the market, such as Fresenius Kabi AG, Asahi Kasei Corporation, and Sartorius AG. Being at the forefront of adopting growth strategies, these companies strive to capitalize on the vast untapped potential of the cell therapy bioprocessing market.
How COVID-19 Impacted the Cell Therapy Bioprocessing Market Growth
The market growth of cell therapy bioprocessing was affected to a certain extent, with more focus put on curbing the onslaught of the COVID-19 pandemic. Research activities halted for a certain period as research institutions had to slow down their trial enrollment process.
In addition, the global pandemic harmed the production and supply chain efforts in the biopharma industries.
However, the market now continues to advance, with many leading businesses planning to make their therapies more accessible.
Navigate Challenges to Success
Researchers are trying to reap the full therapeutic and commercial benefits of cell therapy bioprocessing technologies. For that, emphasis must be placed on overcoming the challenges regarding today’s existing capabilities to generate clinical-grade cells at commercially relevant scales.
However, the development process for bringing cell therapies to patients is highly intricate. The process involves multiple bio-production and bioprocessing steps that need to be executed optimally to confirm the required safety and effectiveness of the final product.
With that said, for cell therapy products to hit the expected success, taking a process-driven approach to bioprocessing operations is critical.
The solution: leveraging a high-end bioprocessing solution with predefined workflow templates for each step in the pipeline
Such a class-leading system like Sapio Sciences’s Bioprocessing solution includes extensive sample, material, and instrument management, charting capabilities, and native data analysis. The result: streamlined operations and seamless collaboration across teams that accelerate product to market.
After decades of relentless efforts, gene and cell therapy bioprocessing is set to flourish incredibly in the coming future. A flurry of recent successes has led to the approval of multiple life-improving therapeutics—and many more are under development.
Company Name: Geeky News
Contact Person: Press Officer
Email: Send Email
Phone: +44 (0)203 800 1212
Address:Parallel House, 32 London Road
Country: United Kingdom
Source: Financial Content